Bionovo shares leap on FDA's green light

Shares of Emeryville, CA-based Bionovo ($BNVI) jumped 25 percent this morning after the developer announced that the FDA has approved its clinical trial plans for its lead drug Menerba, which is in development as a new treatment for hot flashes. "As anticipated, they agreed with our overall clinical development plan which included the number of clinical trials, number of subjects and length of exposure as well as non-clinical studies necessary for New Drug Application submission for a non-estrogen drug such as Menerba. They also provided useful suggestions for improving the clinical trial protocols," said Mary Tagliaferri, M.D., Bionovo's president and CMO. Bionovo release

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.